Ultima Genomics partners with Sentieon and Google DeepVariant to deliver high-performance variant calling

NEWARK, Calif., May 31, 2024 /PRNewswire/ -- Ultima Genomics, Inc. today announced partnerships with Sentieon and Google DeepVariant to offer highly accurate and accelerated variant calling for customers who wish to run pipelines at scale. Both DeepVariant and Sentieon have developed Ultima-specific machine learning models which will be made available in the coming months. Ultima's early access customers will be offered a Sentieon license to process Ultima data at no cost through the end of 2022.

Over the last 5 years, Ultima Genomics has developed a fundamentally new sequencing architecture designed to scale beyond conventional approaches, including completely different flow cell engineering, sequencing chemistry, and machine learning.Ultima is currently in an early access program for the UG 100™, its first high-throughput NGS instrument using this new technology architecture which enables customers to generate high-quality sequencing data at a cost of $1/Gb.

Ultima's mission is to continuously drive the scale of genomic information, said Gilad Almogy, CEO of Ultima Genomics. As we prepare to launch our first high-throughput sequencer, we are excited to partner with informatics leaders such as Google and Sentieon to continually improve and accelerate the generation of high-quality data at scale.

Google DeepVariant

DeepVariant is an open-source technology that identifies genetic variants in sequencing data using deep learning. DeepVariant is noted for its high accuracy, with awards in multiple PrecisionFDA challenges, and for its extensibility to new sequencing methods. DeepVariant is available under the BSD open source license.